These statements are based on current expectations of future events

Forward-Looking Statements – This press release contains ‘forward-looking statements ‘within the meaning of the Private Securities Litigation Reform Act of 1995 . These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results may vary significantly. Of the Company’s expectations and projections Risks and uncertainties include general industry conditions and competition, economic conditions, interest rate and exchange rate fluctuations, technological advances and patents attained by competitors; challenges in new product development, including obtaining regulatory approvals, domestic and foreign health care reforms and governmental laws and regulations and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors could in Exhibit 99 of the Company’s Annual Report on Form 10 – K for the fiscal year ended 28 December 2003. Copies of this Form 10-K are available online or on request from the Company. The company assumes no obligation to update any forward-looking statements to reflect new information or future events or developments.

However, Koen added, considerable work needs to be done the the full clinical potential of this compound. Since the compound tolerated safe and well tolerated in Phase I studies in healthy volunteers will be R207910 now tested in people with active pulmonary tuberculosis. Andries’ coauthors are Peter Verhasselt, Hinrich G hlmann, Jean-Marc Neefs, Hans Winkler, Jef Van Gestel, Philip Timmerman and Didier de Chaffoy at Johnson & Johnson Pharmaceutical Research & Development, in Beerse, Belgium, Jerome? Guillemont at Johnson & Johnson Pharmaceutical Research & Development, in Val de Reuil, France, Min Zhu at Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ; Ennis Lee , and Peter Williams at Johnson & Johnson Pharmaceutical Research & Development, in High Wycome, UK; Emma Huitric and Sven Hoffner at the Swedish Institute for Infectious Disease Control Solna, Sweden;? Emmanuelle Cambau, Chantal Truffot – Pernot, Nacer Lounis and Vincent Jarlier on Piti? Salp tri re – School of Medicine in Paris, France. Nacer Lounis is currently at Johns Hopkins University School of Medicine in Baltimore, The study of Johnson & Johnson Pharmaceutical Research & Development, and animal work was supported in Paris grants from Association grants from Association Francaise Raoul Follereau Francisco, INSERM and Minist re de l’Education Nationale et de la? Research.

It is the fifth year of the SunSmart campaign, Instructs from the British Department of Health which is intended to increase awareness of the importance of out of solar shading and detection against skin cancer.

Other articles from category "ultrasound":

Random articles